20 results about "Kidney dysfunction" patented technology

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The present invention relates to certain SGLT-2 inhibitors for treating and / or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).

The invention provides a risk prediction model processing method and device for a patient with coronary heart disease complicated with renal insufficiency, and introduces a machine learning technology to configure a risk prediction model for the patient with coronary heart disease complicated with renal insufficiency under the condition of paying attention to the neglected relationship between coronary heart disease complicated with renal insufficiency and hospitalization death in the prior art. Further specific optimization is continuously carried out on characteristic variable indexes related to risk prediction logic of the patient with coronary heart disease and renal insufficiency layer by layer in a deep aspect, so that the incidence relation between the patient with coronary heart disease and renal insufficiency and hospitalization death can be deeply captured; the hospitalization death risk prediction work of the patient with coronary heart disease and renal insufficiency is completed with high precision, accurate data support is provided for hospitalization risk assessment and hospitalization management work of the patient with coronary heart disease and renal insufficiency, and then better medical service quality and safety guarantee are provided.

The present invention relates to a method for measuring post-translational modification of proteins in a subject. The method comprises recording infrared radiation in a predetermined wave number range attenuated by an integument of the subject, wherein the integument is still attached to the subject; and comparing the attenuation of the infrared radiation to a predetermined value in order to obtain information about post-translational modification of proteins in the integument. The present invention also relates to a corresponding system and post-translationally modified integument proteins as markers for in vivo diagnosis of diseases, such as diabetes or renal insufficiency.

The invention relates to a traditional Chinese medicine composition for treating acute kidney injury and a preparation method, and belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-30 parts of raw radix astragali; 10-15 parts of codonopsis pilosula; 10 parts of rhizoma pinellinae praeparata; 10 parts of pericarpium citri reticulatae; 15 to 30 parts of loofah sponge; 15 to 30 parts of serissa japonica; and 15-30 parts of rhizoma smilacis glabrae. The traditional Chinese medicine composition disclosed by the invention has two treatment methods of tonifying qi and relieving turbidity, realizes multiple ways, treats both symptoms and root causes, is promoted to be new, has the functions of tonifying qi and relieving turbidity, has a remarkable clinical effect on treating acute renal insufficiency, and has a very good effect in the aspects of improving renal functions and protecting kidneys.

A direct sodium removal (“DSR”) infusate regimen and methods of use are provided for removing sodium and reducing fluid overload in patients with severe renal dysfunction and / or heart failure, in which a patient has at least a first DSR session with a first DSR infusate having no or low sodium that is instilled into a patient's peritoneal cavity for a first dwell period to cause sodium and excess fluid to migrate to the patient's peritoneal cavity, and thereafter, the patient may undergo conventional dialysis to rebalance the patient's fluid and sodium levels.

The present disclosure relates to an animal food composition including from about 0.3 g / Mcal to about 0.8 g / Mcal of magnesium or a salt thereof, for use in a method for treating and / or preventing a mineral bone disorder, especially mineral bone disorder associated with hypercalcemia, in a companion animal that is affected by, or at risk to be affected by, a kidney dysfunction.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a multi-component traditional Chinese medicine external lotion for improving the itching symptom of a chronic kidney disease patient, which is technically characterized in that the lotion is prepared by extracting, concentrating and preparing raw rehmannia root, moutan bark, fructus kochiae, cortex dictamni, salvia miltiorrhiza, radix angelicae sinensis, radix polygoni multiflori preparata, radix sophorae flavescentis and borneol according to a specific weight part ratio. The scheme of the invention integrates treatment methods of nourishing kidney and yin, promoting blood circulation to remove blood stasis, clearing heat and expelling dampness, and cooling blood and dispelling wind aiming at the core pathogenesis of CKD itching of liver and kidney yin deficiency, damp turbidity and blood stasis and skin dystrophy, and is assisted with borneol to promote penetration. Compared with the prior art, the traditional Chinese medicine composition is scientific in formula compatibility, treats both symptoms and root causes and has synergistic interaction; moreover, the scheme of the invention directly acts on the pruritus skin in the form of external lotion, has the advantages of quick response, convenience in use and high safety, is particularly suitable for CKD patients with renal insufficiency, and can obviously relieve pruritus and improve life quality and sleep.

The application belongs to the technical field of functional microorganisms, and discloses application of Pediococcus pentosaceus A21243 in lowering blood uric acid and improving kidney function, and provides application of the Pediococcus pentosaceus A21243 in preparing products for preventing or treating nephropathy and hyperuricemia, wherein the Pediococcus pentosaceus is Pediococcus pentosaceus A21243, and the preservation number is GDMCC NO:63749. The Pediococcus pentosaceus A21243 has the effects of improving and delaying kidney dysfunction caused by hyperuricemia, hyperglycemia and cisplatin, meanwhile, the strain can inhibit the activity of purine metabolism related enzymes in the uric acid generation pathway, such as inhibiting the activity of xanthine oxidase (XOD), purine nucleoside phosphorylase (PNP) and adenosine deaminase (ADA), promote the excretion of uric acid through the intestinal feces, regulate the oxidative stress disorder caused by hyperuricemia, and achieve the beneficial effect of lowering blood uric acid.

The invention relates to the technical field of biology and information, and discloses an anti-infection clinical decision support system, which comprises the following modules: a various antibacterial drug characteristic module (1); an antibacterial drug pharmacokinetic module (2); a renal insufficiency dose adjustment module (3), wherein the renal insufficiency dose adjustment module (3) comprises a renal insufficiency dose adjustment-free drug module (31) and a creatinine clearance rate calculation module (32); a liver insufficiency dose adjustment module (4), wherein the liver insufficiency dose adjustment module (4) comprises a liver function impairment Child-Pugh grading module (41) and a liver insufficiency dose adjustment-free drug module (42); a national bacterial drug resistance statistics module (5); and a drug antibacterial spectrum query module (6). According to the anti-infection clinical decision support system, through cooperative operation of the six modules, all-around support is provided for clinical anti-infection diagnosis and treatment.

The disclosure is directed to methods for preventing or treating cardiovascular disease and kidney dysfunction in certain patient populations which involve determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject, and performing various therapeutic interventions based on the suPAR level in the sample.

The present invention relates to the role of ADAMTS12 protein (A Disintegrin And Metalloproteinase with ThromboSpondin motifs 12 protein) in the development of chronic kidney disease, in particular progressive chronic kidney disease and renal fibrosis. In particular, the present invention relates to methods for identifying compounds that bind to the ADAMTS12 protein and to the use of ADAMTS12 protein for screening and identifying ADAMTS12-interacting and ADAMTS12-inhibiting compounds. The present invention further relates to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit the ADAMTS12 protein.

This invention discloses a copper dicyclopentyl dithiocarbamate compound and its applications, relating to the field of pharmaceutical chemistry, with the molecular formula C0. 22 H 36 CuN2S4, with a central copper ion and two dicyclopentyl dithiocarbamate ligands coordinated via sulfur atoms to form a four-coordinate planar square structure, or its pharmaceutically acceptable salts, solvates, crystal forms, or hydrates. This invention utilizes a novel chemical entity of dicyclopentyl-substituted copper dithiocarbamate, leveraging the greater steric hindrance and lipophilicity advantages of its cyclopentyl structure, as well as its selective response to the high-copper microenvironment of cholangiocarcinoma. Furthermore, it exhibits strong targeting, achieving high enrichment in liver and cholangiocarcinoma tissues, broadening the therapeutic index. Simultaneously, by avoiding the inhibition of systemic ALDH2 activity, it eliminates the alcohol-like toxicity caused by acetaldehyde accumulation. Moreover, it does not cross the blood-brain barrier, exhibits no significant neurotoxicity or cardiotoxicity, is patient-friendly for those with renal insufficiency, and demonstrates high safety.

The invention belongs to the technical field of biology, and particularly relates to application of lupeol to preparation of a medicine for preventing or treating renal injury caused by cis-platinum. The invention discovers that the natural compound lupeol has a potential protection effect on the renal injury caused by the cis-platinum for the first time, and in-vivo and in-vitro models prove that the lupeol remarkably relieves renal dysfunction, tissue pathological injury and rising of renal injury markers caused by the cis-platinum, inhibits cell apoptosis and promotes proliferation of renal tubular cells. A transcriptome sequencing result shows that lupeol enhances cell survival and proliferation by activating a PI3K / Akt signal channel, regulates an Nrf2 channel to resist oxidative stress, inhibits nuclear translocation of NF [kappa] B, reduces pro-inflammatory cytokines and inhibits inflammatory response. Results show that lupeol may become a choice for relieving renal toxicity of cis-platinum.

The invention provides siRNA (small interfering Ribonucleic Acid) of targeted liver xanthine oxidoreductase and application of the siRNA to treatment of hyperuricemia and renal insufficiency related to the hyperuricemia. The siRNA targets a liver xanthine oxidoreductase (XOR) gene, the XOR gene has a nucleotide sequence as shown in SEQ ID No: 149, a nucleotide sequence of a sense strand of the siRNA comprises at least 15 nucleotides, and a target sequence of the siRNA comprises at least 15 continuous nucleotides located in the 430 -4400 nucleotide range of the nucleotide sequence of the XOR gene. By applying the siRNA to the treatment of hyperuricemia and related renal insufficiency, a novel treatment strategy for treating hyperuricemia and protecting renal function can be provided, and the strategy is efficient and has few side effects.

The present application relates to the technical field of external treatment of traditional Chinese medicine, and specifically discloses a traditional Chinese medicine acupoint paste for regulating metabolism, a preparation method and application thereof. In view of the deficiency of the existing part of the metabolism regulation paste product in focusing on the function of a single Zang organ, the present application provides a traditional Chinese medicine acupoint paste based on the same regulation theory of liver, spleen and kidney. The paste is composed of the following medicinal materials in parts by weight: 20-30 parts of Radix Astragali, 12-15 parts of Radix Bupleuri, 15-20 parts of Herba Epimedii, 10-12 parts of Rhizoma Chuanxiong, 10-12 parts of Paeonia, 15-18 parts of Rhizoma Corydalis, 10-15 parts of Radix Atractylodis, 15-18 parts of Rhizoma Cyperi and 4-5 parts of Borneolum Syntheticum. The present application is used for the comprehensive regulation of the functions of liver, spleen and kidney through the synergistic effect of drugs and specific acupoints, and is suitable for the auxiliary regulation of the metabolic disorder state caused by liver stagnation, spleen dysfunction and kidney dysfunction.

The present disclosure relates generally to methods and compositions comprising trigonelline for treating or preventing diseases or conditions associated with muscle decline and / or renal dysfunction. In addition, the invention relates to methods and compositions comprising trigonelline for slowing the progression of glomerular filtration rate (GFR) and / or reducing glomerular vitreous lesion injury and / or increasing lean body mass of the muscle. In addition, methods and compositions comprising trigonelline are disclosed for increasing lean body mass of the muscle and / or increasing muscle fiber size. Also disclosed are methods for increasing the level of at least one nicotinamide adenine dinucleotide and compositions comprising trigonelline. Methods and compositions comprising trigonelline for increasing muscle stem cells and / or reducing muscle stem cell decline are also disclosed.

This invention relates to a device and medium for assessing the risk of inadequate bowel preparation in patients taking oral magnesium sulfate. The device includes: a data acquisition module for acquiring various risk assessment indicators for patients taking oral magnesium sulfate, including indicators of stroke or dementia, inflammatory bowel disease, heart or kidney failure, colonic stenosis, medication history, dietary type, taste of laxatives, preferred laxatives, history of failed bowel preparation, adverse events, complete administration, and yellow watery stools; and a bowel preparation inadequate risk assessment module for assigning values ​​to the acquired risk assessment indicators to assess the risk of inadequate bowel preparation. Compared with existing technologies, this invention has the advantages of comprehensively and accurately assessing the risk of inadequate bowel preparation, and has good discrimination and calibration.

The application belongs to the technical field of disease diagnosis, and particularly relates to the use of CX3CL1 as a biomarker of acute type A aortic dissection. The application finds that CX3CL1 is a key inflammatory mediator of acute type A aortic dissection, and its plasma level is significantly positively correlated with neutrophil infiltration, IL-6, IL-8, IL-10, D-dimer and NT-proBNP. It is proved by characteristic curve analysis that there is a significant correlation between the CX3CL1 level and the severity of ATAAD. By evaluating the expression level of CX3CL1 protein in peripheral blood of a subject, an evaluation result related to the risk of suffering from acute type A aortic dissection is generated, non-invasive, fast and low-cost detection can be realized, and the problem that patients with renal dysfunction or contrast agent allergy cannot use CT angiography for diagnosis is solved.

To provide an objective and noninvasive method for examining renal dysfunction of a cat.SOLUTION: A method for examining renal dysfunction in a cat, comprising a step of measuring a level of at least one D-amino acid selected from the group consisting of D-tyrosine, D-methionine, D-tryptophan, D-ornithine, and D-histidine in urine of a subject.SELECTED DRAWING: None